Elevance Health Inc. (ELV) — Fair Value Analysis
Base-case fair value (P50): $403.06 · Current price: $417.89 · Verdict: Fairly Valued
The Verdict on ELV
Elevance Health (ELV) is currently Fairly Valued based on our comprehensive Monte Carlo simulations, which rigorously model thousands of future operational and market scenarios to determine intrinsic value. The stock is presently trading at $417.89, positioning it very close to our median fair value (P50) of $403.06. This tight convergence yields a minimal -3.5% from current levels, indicating that ELV's market valuation largely aligns with its intrinsic worth derived from our robust simulation framework. This outcome suggests the market has efficiently priced ELV based on available information and projected performance.
How ELV stacks up against Healthcare
When benchmarked against its Healthcare sector peers, Elevance Health’s operational and financial health earns an average quality tier rating. This assessment helps contextualize ELV’s current trading price of $417.89 relative to its median fair value of $403.06. An average quality tier implies that while ELV possesses solid fundamentals, it doesn't present an exceptional competitive advantage or significant distress to warrant a substantial premium or discount versus its sector. This supports the Fairly Valued verdict, as the company’s intrinsic value appears consistent with a fundamentally sound, yet not outstanding, industry player.
What this means for investors
For investors, the Fairly Valued verdict for ELV suggests that the current market price of $417.89 already reflects the company’s projected performance and industry standing as modeled through our Monte Carlo simulations. The modest -3.5% towards the P50 fair value of $403.06 indicates that significant immediate capital appreciation based purely on a valuation gap is unlikely. While our simulations encompass a broad range of outcomes, from a challenging downside scenario to a robust bull case, this alignment reinforces a neutral investment stance for ELV. FairCurve provides a dynamic framework for understanding these complex valuations. To gain deeper insight into ELV's full bear-case and bull-case distribution, including probability of upside, and to track its fair value as new fundamentals are released, sign up for a free FairCurve account.
Frequently Asked Questions
Is ELV overvalued or undervalued right now?
Based on our Monte Carlo simulations, Elevance Health (ELV) is currently Fairly Valued. Its current trading price of $417.89 is very close to our median fair value (P50) of $403.06.
What is the bear case and bull case for ELV?
FairCurve's Monte Carlo simulations generate a full distribution of potential fair values, including detailed bear-case (P10) and bull-case (P90) price targets. This complete outlook, alongside the probability of upside, is exclusively available with a free FairCurve account.
How does FairCurve calculate ELV's fair value?
FairCurve calculates ELV's fair value using sophisticated Monte Carlo simulations, running thousands of forward-looking financial scenarios. This process generates a robust distribution of potential intrinsic values, accounting for various market and operational factors.
How can I track ELV's fair value as it changes?
You can track ELV's fair value by adding it to a free FairCurve watchlist. This provides daily updates on its valuation and instantly re-evaluates its fair value whenever new financial fundamentals or earnings are released.